Levels of VCAM-1 and ICAM-1 in serum of active and inactive Systemic Lupus Erythematosus patients as biochemical markers for risk of cardiovascular disease

Hajer Walid; Ghid H Abdulhadi; Mohammad H Munshid

doi:10.32007/jfacmedbagdad.1952

المؤلفون

Hajer Walid College of Medicine https://orcid.org/0009-0009-8181-6303
Ghid H Abdulhadi Baghdad University , College of Medicine, Dept. Of clinicalBiochemistery https://orcid.org/0000-0002-8645-7217
Mohammad H Munshid Baghdad University , College of Medicine, Dept. Of Medicine https://orcid.org/0000-0001-8521-5876

DOI:

https://doi.org/10.32007/jfacmedbagdad.1952

الكلمات المفتاحية:

SLE، Atherosclerosis، VCAM، ICAM، CVD، Lipid profile

الملخص

الخلفية العلمية: تمثل المضاعفات القلبية الوعائية إحدى نتائج أمراض المناعة الذاتية المزمنة مثل الذئبة الحمامية الجهازية (الذئبة الحمراء)، والتي لها معدلات كبيرة من الوفيات والمراضة. يمكن حدوث عسر شحميات الدم عن طريق الأدوية الستيرويدية، والتي تُعطى بشكل متكرر لمرضى الذئبة الحمراء وتعتبر أحد عوامل الخطر الرئيسية لأمراض القلب والأوعية الدموية.

الأهداف: حاولت هذه الدراسة التحقق من وجود ارتباط محتمل بين VCAM-1 و ICAM-1 في المرضى العراقيين الذين تم تشخيص إصابتهم بالذئبة الحمامية الجهازية كعوامل خطر لتصلب الشرايين وعلاقتها بمخاطر القلب والأوعية الدموية.

المنهجية: تم تضمين 100 مريض و 50 شخص يبدون بصحة جيدة في هذه الدراسة. جميع المرضى في قسم أمراض الروماتيزم، مستشفى بغداد / المدينة الطبية في الفترة من 1 كانون الأول 2021 إلى 1 آذار 2022 وعولجوا جميعاً بأدوية مضادة للملاريا كمثبطات مناعية مثل الكلوروكين أو الهيدروكسي كلوروكين. تم تقسيمهم وفقًا لمؤشر نشاط مرض .(SLEDAI≥10) كمجموعة نشطة و(SLEDAI˂10) كمجموعة غير نشطة

النتائج: كان مستوى VCAM و ICAM في المصل مرتفعا بشكل ملحوظ في جميع مجموعات الدراسة لمرضى الذئبة الحمراء. كان متوسط ± الإنحراف المعياري ل VCAM (271.9 ± 63.90) ، (247.9 ± 82.92 و (97.7 ± 24.69) في عناصر تحكم نشطة وغير نشطة وعناصر تحكم على التوالي. وكان متوسط ± الإنحراف المعياري ل ICAM (3.1±0.91)، (2.7 ± 0.79) و (1.8 ± 0.22) في عناصر التحكم النشطة وغير النشطة والضوابط على التوالي. زادت القيم تدريجياً مع زيادة نشاط المرض. كانت المنطقة تحت المنحنى (AUC) لـ ICAM و VCAM (0.802) ، ((0.776 في مرضى SLE النشطين و (0.858) ، (0.674) في مرضى SLE غير النشطين. ومع ذلك ، كانت AUC لـ VCAM و ICAM في المجموعة النشطة هي الأعلى.

الإستنتاج: في مرضى SLE، قد تعمل مستويات مصل VCAM-1 و ICAM-1 كمؤشرات للكشف عن المرض وتمايز الخطورة، وقد تكون مرتبطة بعدد الآفات التاجية لدى الأشخاص المعرضين لخطر الإصابة بأمراض القلب والأوعية الدموية.

التنزيلات

تنزيل البيانات ليس متاحًا بعد.

المراجع

Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. Journal of Autoimmunity. 2021 May 1;119:102615. https://doi.org/10.1016/j.jaut.2021.102615

Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Annals of the rheumatic diseases. 2021 Jan 1;80(1):14-25. https://doi.org/10.1136/annrheumdis-2020-218272

Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Current Vascular Pharmacology. 2020 Nov 1;18(6):549-65.

https://doi.org/10.2174/1570161118666191227101636

Justiz Vaillant AA, Goyal A, Bansal P, Varacallo M. Systemic lupus erythematosus (SLE). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright. 2020.

Mok CC, Tse SM, Chan KL, Ho LY. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus. 2018 Apr;27(5):722-7. https://doi.org/10.1177/0961203317739129

Ruan Y, Guo Y, Zheng Y, Huang Z, Sun S, Kowal P, et al. Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle-income countries: results from SAGE Wave 1. BMC public health. 2018 Dec;18(1):1-3.

https://doi.org/10.1186/s12889-018-5653-9

Leone P, Cicco S, Prete M, Solimando AG, Susca N, Crudele L, et al. Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. Clinical and experimental medicine. 2020 Feb;20(1):11-9. https://doi.org/10.1007/s10238-019-00600-8

Roldan PC, Greene ER, Qualls CR, Sibbitt WL Jr, Roldan CA. Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus. Rheumatol Int. 2019;39(6):1027-36.

https://doi.org/10.1007/s00296-019-04267- y

Benagiano M, Borghi MO, Romagnoli J, Mahler M, Della Bella C, Grassi A, et al, 2019. Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. Haematologica, 104(12), p.2519.

https://doi.org/10.3324/haematol.2018.209536

Atta AM, Silva JP, Santiago MB, Oliveira IS, Oliveira RC, Sousa Atta ML. Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus. Clinical Rheumatology. 2018 Jun;37(6):1539-46.

https://doi.org/10.1007/s10067-018-4051-0

Andersen CJ. Impact of Dietary Cholesterol on the Pathophysiology of Infectious and Autoimmune Disease. Nutrients. 2018;10(6):764. https://doi.org/10.3390/nu10060764

Frieri M, Stampfl H, Systemic lupus erythematosus and atherosclerosis: review of the literature, Autoimmun. Rev. 15 (2016) 16-21. https://doi.org/10.1016/j.autrev.2015.08.007

Huang H, Liu X, Chen D, Lu Y, Li J, Du F, et al Melatonin prevents endothelial dysfunction in SLE by activating the nuclear receptor retinoic acid-related orphan receptor-α, International Immunopharmacology,Volume 83,2020,106365,ISSN 1567-5769.

https://doi.org/10.1016/j.intimp.2020.106365

Lewandowski LB, Kaplan MJ. Update on cardiovascular disease in lupus, Curr. Opin. Rheumatol. 28 (2016) 468-476. https://doi.org/10.1097/BOR.0000000000000307

Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7: 803-815 https://doi.org/10.1038/nri2171

(16) Santos JCD, Cruz MS, Bortolin RH, Oliveira KMD, Araújo JNGD, Duarte, VHR, et al, 2018. Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions. Clinics, 73. https://doi.org/10.6061/clinics/2018/e203

Yu KY, Yung S, Chau MK, Tang CS, Yap DY, Tang AH, et al. Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis. Lupus. 2021 Jun;30(7):1039-50. https://doi.org/10.1177/09612033211004727

Smith E, Corkhill R, Midgley A, Watson L, Jones C, Marks S, et al. Urinary VCAM-1 as a biomarker of lupus nephritis disease activity. Pediatric Rheumatology. 2014 Sep;12(1):1-2.

https://doi.org/10.1186/1546-0096-12-S1-P108

Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, et al., 2009. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis research & therapy, 11(6), pp.1-11.

https://doi.org/10.1186/ar2878

Guo Liu RN, Cheng QY, Zhou HY, Li BZ and Ye DQ. 2020. Elevated blood and urinary ICAM-1 is a biomarker for systemic lupus erythematosus: a systematic review and meta-analysis. Immunological Investigations, 49(1-2), pp.15-31.

https://doi.org/10.1080/08820139.2019.1624769

Wang D, Cai X. Smooth ROC curve estimation via Bernstein polynomials. PLoS One. 2021;16(5):e0251959. Published 2021 May 25.

https://doi.org/10.1371/journal.pone.0251959

Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1982 Nov;25(11):1271-7.

https://doi.org/10.1002/art.1780251101

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1992 Jun;35(6):630-40. https://doi.org/10.1002/art.1780350606

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. https://doi.org/10.1093/clinchem/18.6.499

Moradi S, Entezari MH, Mohammadi H, Jayedi A, Lazaridi AV, Kermani MA, et al. Ultra-processed food consumption and adult obesity risk: a systematic review and dose-response meta-analysis. Critical reviews in food science and nutrition. 2021 Jun 21:1-2. https://doi.org/10.1080/10408398.2021.1946005

Lecube A, Sánchez E, Monereo S, Medina-Gómez G, Bellido D, García-Almeida JM, et al. Factors Accounting for Obesity and Its Perception among the Adult Spanish Population: Data from 1,000 Computer-Assisted Telephone Interviews. Obes Facts 2020;13:322-332. doi: 10.1159/000508111. https://doi.org/10.1159/000508111

Santos MJ, Carmona-Fernandes D, Canhao H, Canas da Silva J, Fonseca JE, Gil V. Early vascular alterations in SLE and RA patients-a step towards understanding the associated cardiovascular risk.

Hoke M, Winter M, Wagner O, Exner M, Schillinger M, Arnold Z, et al. The impact of selectins on mortality in stable carotid atherosclerosis. Thromb Haemost. 2015;114(3):632-8, https://doi.org/10.1160/TH14-12-1014

Zhou B, Xia Y, She J. Dysregulated serum lipid profile and its correlation to disease activity in young female adults diagnosed with systemic lupus erythematosus: a cross-sectional study. Lipids in health and disease. 2020 Dec;19(1):1-6.

https://doi.org/10.1186/s12944-020-01232-8

Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity?, Seminars in Arthritis and Rheumatism, Volume 45, Issue 5, 2016, Pages 604-610, ISSN 0049-0172.

https://doi.org/10.1016/j.semarthrit.2015.10.010

Szabo MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65(2):543-550. https://doi.org/10.1007/s12026-016-8892-9

Atik N, Hayati RU, Hamijoyo L. Correlation Between Steroid Therapy and Lipid Profile in Systemic Lupus Erythematosus Patients. Open Access Rheumatology: Research and Reviews. 2020;12:41. https://doi.org/10.2147/OARRR.S245662

Tao CY, Shang J, Chen T, Yu D, Jiang YM, Liu D, Cheng GY, et al. 2019. Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Medicine, 98(14).

https://doi.org/10.1097/MD.0000000000015030

patients: a systematic review and meta-analysis. Medicine, 98(14).